News and Events
Stay up to date with news and events
2024: Year in Review
As we wave goodbye to 2024, the HDBuzz team reflects on a year marked by significant progress, challenges, and hope. From breakthroughs at the lab…
2024 HDBuzz Prize: A NEAT new dance partner for Huntingtin
Proteins are like molecular dancers, with the cell acting as their dance floor. Proteins pair up with various partners to perform elaborate dances. Depending on…
Beta-blockers associated with delayed onset and decreased progression of Huntington’s disease
Research led by Dr. Peg Nopoulos from the University of Iowa used the Enroll-HD database to answer a key question: “How does beta-blocker use influence…
Interim update from Vico Therapeutics on their CAG-targeting drug, VO659
Vico Therapeutics recently presented at several conferences to share an interim update on their Phase 1/2a clinical trial testing their drug called VO659, which targets…
Going boldly: First person treated in Phase 1 clinical trial by Alnylam Pharmaceuticals
On December 3, 2024 we received word that the very first person received a new drug, called ALN-HTT02, as part of a Phase 1 trial…